SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-236202
Filing Date
2023-09-15
Accepted
2023-09-15 16:24:15
Documents
14
Period of Report
2023-09-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d507712d8k.htm   iXBRL 8-K 37504
2 EX-2.1 d507712dex21.htm EX-2.1 53249
  Complete submission text file 0001193125-23-236202.txt   270731

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amam-20230911.xsd EX-101.SCH 4117
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amam-20230911_def.xml EX-101.DEF 14409
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE amam-20230911_lab.xml EX-101.LAB 24012
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amam-20230911_pre.xml EX-101.PRE 15257
8 EXTRACTED XBRL INSTANCE DOCUMENT d507712d8k_htm.xml XML 6147
Mailing Address 10975 NORTH TORREY PINES ROAD LA JOLLA CA 92037
Business Address 10975 NORTH TORREY PINES ROAD LA JOLLA CA 92037 (858) 875-2400
Ambrx Biopharma Inc. (Filer) CIK: 0001836056 (see all company filings)

IRS No.: 571147346 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40505 | Film No.: 231259056
SIC: 2836 Biological Products, (No Diagnostic Substances)